Infographics
-
Biologic Drug Substance And Drug Product Preferred Provider Use
4/15/2019
ISR data shows the majority of those who outsource biologic drug substance and drug product use a preferred provider approach to outsourcing, and average about four CMOs on their lists.
-
Customer Loyalty In Small Molecule Drug Substance Manufacturing
4/15/2019
In Q4, 2018, ISR surveyed 134 sponsors who outsource drug substance manufacturing for small molecule compounds to gain insight into their CMO loyalty. ISR computes customer loyalty as an index that consists of overall satisfaction, willingness to recommend, and likelihood to use the CMO again.
-
How Do Experience And Capacity Impact Oral Dose Outsourcing?
2/25/2019
In Q2 2018, ISR asked 44 outsourcers of oral solid dose drug product manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources.
-
Outsourcing Drivers By Company Size
2/25/2019
In Q4 2018, ISR surveyed 121 outsourcers of large molecule drug substance manufacturing to understand their primary reason for working with CMOs for biologic API. The data show respondents from small companies, with an annual R&D spend under $1B, are more likely to use CMOs for all of their manufacturing needs than respondents from large pharma companies (61% vs 24%).
-
What Factors Influence Outsourcing Model Changes
12/4/2018
In Q2, 2018, ISR asked 100 people who outsource manufacturing to describe a scenario that has led or would lead their organization to change outsourcing models.
-
Outsourcing Impact Of Focus On Innovative Treatment
11/15/2018
In Q4, 2017, ISR asked a follow-up question to respondents who agreed that their company’s focus on developing new innovative treatments will impact its outsourcing practices.
-
Approaches To CMC Involvement Across Drug Development
9/18/2018
In Q42017, ISR interviewed fifteen tenured CMC professionals at top 50 Pharma companies to learn when during the drug development cycle CMC has its greatest involvement and influence.
-
Small Molecule Outsourcing Drivers
7/16/2018
In Q42017, ISR surveyed sponsors who outsource small molecule API and small molecule drug product manufacturing to inquire about their company’s main driver for working with contract manufacturers.
-
Small Molecule API Contract Manufacturer Loyalty
6/25/2018
In Q42017, ISR surveyed 227 sponsors who outsource small molecule API to gain insight into customer loyalty. CMO loyalty is computed as an index that consists of overall satisfaction, willingness to recommend, and the likelihood of using the contract manufacturer again. The data below show companies with ten or more responses from recent users and an industry average derive from all CMOs included in the research; their loyalty component scores are aggregated, averaged and then weighted based on the number of customer interactions.
-
Benefits Of Using Preferred Providers For Clinical Development Outsourcing
5/22/2018
Results from a Q1 2018 ISR survey of 117 outsourcers at biopharmaceutical sponsors regarding the use and performance of a variety of clinical development outsourcing models.